Adherence to antiretrovirals among US women during and after pregnancy

Journal of Acquired Immune Deficiency Syndromes

Volumn 48, Issue 4, 2008, Pages 408-417

  Bardeguez, Arlene D ^a   Lindsey, Jane C ^b   Shannon, Maureen ^c   Tuomala, Ruth E ^d   Cohn, Susan E ^e   Smith, Elizabeth ^f   Stek, Alice ^g   Buschur, Shelly ^h   Cotter, Amanda ⁱ   Bettica, Linda ^a   Read, Jennifer S ^j  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY OF MIAMI   (United States)

^j EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

more..

Author keywords

Adherence; Depression; HIV 1 infection; Pregnancy; Substance use; Viral suppression

Indexed keywords

CANNABIS; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VITAMIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; SELF REPORT; TABLET; UNITED STATES; VIRUS LOAD; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMPARATIVE STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; INFANT; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL CARE; PROSPECTIVE STUDY; QUESTIONNAIRE; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; PATIENT COMPLIANCE; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL CARE; PROSPECTIVE STUDIES; QUESTIONNAIRES; TABLETS; UNITED STATES; VIRAL LOAD;

EID: 50649090553     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31817bbe80     Document Type: Article

References (35)

1. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338: 853-860.
2. Haubrich RH, Little SJ, Currier JS, et al. The value of patient reported adherence to antiretroviral therapy in predicting virologic and immuno-logic response: California Collaboration Treatment Group. AIDS. 1999; 13:1099-1107.
3. Paterson DL, Swindells S, Mohr JA, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
4. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar rates of adherence favor different virologic outcomes for patients treated with non-nucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40:158-163.
5. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939-941.
6. Murphy DA, Wilson CM, Durako SJ, et al. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care. 2001;13:27-40.
7. Lucas GM, Cheever LW, Chaison RE, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;71:251-259.
8. Starace F, Ammassari A, Trotta MP, et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;(Suppl 3):S136-S139.
9. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;10:756-765.
10. Stone V, Hogan J, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: survey of women in the HER study. J Acquir Immune Defic Syndr. 2001;28:124-131.
11. Miller LG, Liu H, Hays RD, et al. Knowledge of antiretroviral regimen dosing and adherence: a longitudinal study. Clin Infect Dis. 2003;36: 514-518.
12. Kalichman SC, Rompa D. Functional health literacy is associated with health status and health-related knowledge in people living with HIV/ AIDS. J Acquir Immune Defic Syndr. 2000;25:337-344.
13. Recommendations for the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Public Health Service Task Force, November 2, 2007. Available at: http://AIDSinfo.nih.gov.
14. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357-366.
15. Wells SL, Pitt J, Colgrove R, et al. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the Women and Infants Transmission Study. AIDS. 2000;14:263-271.
16. Johnson VA, Petropoulos CJ, Woods CR, et al. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. J Infect Dis. 2001;183:1688-1693.
17. Brogly S, Read JS, Shapiro D, et al. Participation of HIV-infected pregnant women in research in the United States. AIDS Res Hum Retroviruses. 2007;23:51-53.
18. Berwick DM, Murphy JM, Goldman PA, et al. Performance of a five-item mental health screening test. Med Care. 1991;29:169-176.
19. Holmes WC. A short psychiatric case finding measure for HIV seropositive outpatients: performance characteristics of the 5 item mental health subscale of the SF-20 in a male seropositive sample. Med Care. 1998;36:237-243.
20. Pagano J, Gauvreau K. Principles of Biostatistics. 2nd ed. Pacific Grove, CA: Duxbury; 2000.
21. Liang KY, Zeger SL. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
22. Longford N. Random Coefficient Models. Oxford, England: Oxford University Press; 1993.
23. Wilson T, Ickovics JR, Fernandez MI, et al. For the Perinatal Guidelines Evaluation Project. Self-reported zidovudine adherence among pregnant women with human immunodeficiency virus infection in four US states. Am J Obstet Gynecol. 2001;184:1235-1240.
24. Ickovics JR, Wilson TE, Royce RA, et al. Prenatal and postpartum zidovudine adherence among pregnant women with HIV: results of a MEMS sub-study from the perinatal guidelines evaluation project. J Acquir Immune Defic Syndr. 2002;30:311-315.
25. Centers for Disease Control and Prevention. Enhanced Perinatal Surveillance - United States, 1999-2001. Atlanta, GA: USDHHS, CDCP; 2004:12,18-19. Special Surveillance Report 4.
26. Lucas GM, Cheever LW, Chaisson RE. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquired Immune Defic Syndr. 2001;27:251-259.
27. Yun LWH, Maravi M, Kobayashi JS, et al. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. J Acquir Immune Defic Syndr. 2005;38:432-438.
28. Osterberg L, Blaschke T. Adherence to medications. N Engl J Med. 2005; 353:487-497.
29. Simpson RJ. Challenges for improving medication adherence. JAMA. 2006;296:2614-2615.
30. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report 1, January 1989 Through 31 July 2007. Available at: www.APRegistry.com. Wilmington, NC: Registry Coordinating Center; 2007.
31. Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr. 2004;36:772-776.
32. Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS. 2002;16:299-300.
33. Acosta E, Zorilla C, Van Dyke R, et al. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials. 2001;2:460-465.
34. Stek A, Mirochnick M, Capprelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS. 2006;20:1931-1939.
35. Miller LG, Liu H, Hays R, et al. Knowledge of antiretroviral regimen dosing and adherence: a longitudinal study. Clin Infect Dis. 2003;36: 514-518.